|
[1] MCPHERSON S, HARDY T, HENDERSON E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:Implications for prognosis and clinical management[J]. J Hepatol, 2015, 62 (5) :1148-1155.
|
|
[2] GOH GB, Mc CULLOUGH AJ. Natural history of nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2016, 61 (5) :1226-1233.
|
|
[3] SANYAL AJ, BRUNT EM, KLEINER DE, et al. Endpoints and clinical trial design for non-alcoholic steatohepatitis[J]. Hepatology, 2011, 54 (1) :344-353.
|
|
[4] HANNAH WN Jr, TORRES DM, HARRISON SA. Nonalcoholic steatohepatitis and endpoints in clinical trials[J]. Gastroenterol Hepatol (NY) , 2016, 12 (12) :756-763.
|
|
[5] VERMA S, JENSEN D, HART J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) [J]. Liver Int, 2013, 33 (9) :1398-1405.
|
|
[6] JANCZYK W, LEBENSZTEJN D, WIERZBICKA-RUCIN'SKA A, et al. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease:A randomized controlled trial[J]. J Pediatr, 2015, 166 (6) :1358-1363.
|
|
[7] LAVINE JE, SCHWIMMER JB, VAN NATTA ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:The TONIC randomized controlled trial[J].JAMA, 2011, 305 (16) :1659-1668.
|
|
[8] SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362 (18) :1675-1685.
|
|
[9] CHEN J, ZHU Y, ZHENG Q, et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis:A meta-analysis[J].Hepatol Res, 2014, 44 (8) :854-862.
|
|
[10] FELDSTEIN AE, ALKHOURI N, De VITO R, et al. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children[J]. Am J Gastroenterol, 2013, 108 (9) :1526-1531.
|
|
[11] HE L, DENG L, ZHANG Q, et al. Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease:A systematic review and meta-analysis[J]. Biomed Res Int, 2017, 2017:9729107.
|
|
[12] RATZIU V, SHEIKH MY, SANYAL AJ, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450in subjects with nonalcoholic steatohepatitis[J]. Hepatology, 2012, 55 (2) :419-428.
|
|
[13] FRIEDMAN SL, RATZIU V, HARRISON SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67 (5) :1754-1767.
|
|
[14] BEDOGNI G, BELLENTANI S, MIGLIOLI L, et al. The fatty liver index:A simple and accurate predictor of hepatic steatosis in the general population[J]. BMC Gastroenterol, 2006, 6:33.
|
|
[15] LEE JH, KIM D, KIM HJ, et al. Hepatic steatosis index:A simple screening tool reflecting nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2010, 42 (7) :503-508.
|
|
[16] ALLER R, IZAOLA O, GMEZ S, et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study[J]. Eur Rev Med Pharmacol Sci, 2015, 19 (16) :3118-3124.
|
|
[17] POLYZOS SA, KOUNTOURAS J, MANTZOROS CS, et al. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease:A randomized controlled trial[J]. Diabetes Obes Metab, 2017, 19 (12) :1805-1809.
|
|
[18] ESLAMPARAST T, POUSTCHI H, ZAMANI F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease:A randomized, double-blind, placebo-controlled pilot study[J]. Am J Clin Nutr, 2014, 99 (3) :535-542.
|
|
[19] JOY TR, MCKENZIE CA, TIRONA RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis:A randomized, placebocontrolled trial[J]. World J Gastroenterol, 2017, 23 (1) :141-150.
|
|
[20] ZHRER E, ALISI A, JAHNEL J, et al. Efficacy of docosahexaenoic acid-choline-vitamin E (DHA-CHO-VE) in paediatric NASH:A randomized controlled clinical trial[J]. Appl Physiol Nutr Metab, 2017, 42 (9) :948-954.
|
|
[21] HARRISON SA, MARRI SR, CHALASANI N, et al. Randomised clinical study:GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis[J]. Aliment Pharmacol Ther, 2016, 44 (11-12) :1183-1198.
|
|
[22] HARRISON SA, DENNIS A, FIORE MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial[J]. PLo S One, 2018, 13 (9) :e0203054.
|
|
[23] BAE JC, LEE WY, YOON KH, et al. Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2 diabetes (CORONA) :A randomized controlled trial[J]. Diabetes Care, 2015, 38 (7) :1245-1252.
|
|
[24] CUI J, PHILO L, NGUYEN P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease:A randomized controlled trial[J]. J Hepatol, 2016, 65 (2) :369-376.
|
|
[25] JEONG JY, SOHN JH, BAEK YH, et al. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease:A placebo-controlled, randomized, phase II trial[J]. World J Gastroenterol, 2017, 23 (32) :5977-5985.
|
|
[26] OH B, CHOI WS, PARK SB, et al. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liverfunction and/or fatty liver:A multi-centre, randomised, doubleblinded, placebo-controlled trial[J]. Int J Clin Pract, 2016, 70 (4) :302-311.
|
|
[27] JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2018.[Epub ahead of print]
|
DownLoad: